Blood samples were collected at baseline, after oral DE, after intravenous dabigatran, and 60 minutes post-injury.
Methodsĭabigatran etexilate (DE) was given orally for 3 days (30 mg/kg bid) and intravenously on day 4 to achieve consistent, supratherapeutic concentrations of dabigatran. Using a porcine model of trauma, this study assessed the ability of prothrombin complex concentrate (PCC), activated PCC (aPCC), recombinant FVIIa (rFVIIa) and a specific antidote to dabigatran (aDabi-Fab) to reverse the anticoagulant effects of dabigatran. However, no specific reversal agents are available for life-threatening bleeding or emergency surgery.
New oral anticoagulants are effective alternatives to warfarin.
0 kommentar(er)
